The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the annual general meeting to be held on Monday 19 August 2024 at 16.00 at the company’s premises at Stortorget 1 in L...
EQL Pharma AB (publ) will publish its interim report for the first quarter, 2024/25, on Thursday, August 8[th], before stock markets opening.
EQL's key product Mellozzan[®] has now gained marketing approval by the Health Authorities in Switzerland, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Pütter...
